Skip to main content
. 2016 Jan 25;7(6):7307–7317. doi: 10.18632/oncotarget.7007

Figure 5. IL-32θ inhibits the tumorigenic ability of HT-29 cells in vivo.

Figure 5

(A) The overexpression of IL-32θ inhibits the growth of colon cancer xenografts. (B) Colon tumors in xenografts. Tumors from mice injected with normal HT-29 cells (Top) or HT-29-IL-32θ cells (Bottom) are shown. Tumors were collected after 26 days. (C) The effects of IL-32θ on tumor tissues were determined by qPCR. The expression levels of mRNAs were normalized to those for B2M. The values presented are relative to those for cells transfected with empty vector. (D) Representative immunohistochemical micrographs (400 × magnification) showing Bmi1, Sox2 and Zeb1 in tumor tissues. Data are presented as the mean ± S.D. **P < 0.005.